Phase 3 Trial of Oral Anti‐Amyloid Agent ALZ‐801/Valiltramiprosate in APOE4/4 Homozygotes with Early Alzheimer’s Disease: Baseline Characteristics and Prevalence of Comorbid Cerebral Amyloid Angiopathy | Publicación